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Background: Previous animal studies have shown that Curcuma longa (turmeric) improves liver function. Turmeric
may thus be a promising ingredient in functional foods aimed at improving liver function. The purpose of the
study is to investigate the hepatoprotective effect of fermented turmeric powder (FTP) on liver function in subjects
with elevated alanine transaminase (ALT) levels.
Methods: A randomised, double-blind, placebo-controlled trial was conducted between November 2010 and April
2012 at the clinical trial center for functional foods of the Chonbuk National University Hospital. The trial included
60 subjects, 20 years old and above, who were diagnosed mild to moderate elevated ALT levels between 40 IU/L
and 200 IU/L. Sixty subjects were randomised to receive FTP 3.0 g per day or placebo 3.0 g per day for 12 weeks.
The treatment group received two capsules of FTP three times a day after meals, for 12 weeks. The primary efficacy
endpoint was change in the ALT levels in the two groups. The secondary efficacy endpoints included its effect on
aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), total bilirubin (TB), and lipid profiles. Safety
was assessed throughout the study using ongoing laboratory tests. Adverse events (AEs) were also recorded.
Results: Sixty subjects were randomised in the study (30 into the FTP group, 30 into the placebo group), and
among them, twelve subjects were excluded from the analysis for protocol violation, adverse events or consent
withdrawal. The two groups did not differ in baseline characteristics. After 12 weeks of treatment, 48 subjects were
evaluated. Of the 48 subjects, 26 randomly received FTP capsules and 22 received placebo. The FTP group showed
a significant reduction in ALT levels after 12 weeks of treatment compared with the placebo group (p = 0.019).
There was also observed that the serum AST levels were significantly reduce in the FTP group than placebo group
(p = 0.02). The GGT levels showed a tendency to decrease, while the serum alkaline phosphatase (ALP), TB, and
lipids levels were not modified. There were no reported severe AEs during this study, or abnormalities observed on
blood glucose, total protein, albumin, blood urea nitrogen (BUN), and creatinine levels.
Conclusion: The data of this trial indicate that FTP is effective and safe, generally well-tolerated without severe AEs,
in the treatment of subjects with elevated ALT levels over a 12 weeks period.
Trial registration: ClinicalTrials.gov: NCT01634256* Correspondence: soowan@jbnu.ac.kr
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The liver plays a major role in detoxification and excre-
tion of many endogenous and exogenous compounds.
Any impairment to its functions may lead to many im-
plications on one’s health. Management of liver diseases
is still a challenge to the modern scientific community
[1]. There are few conventional drugs that can stimulate
liver function and offer hepatoprotection or help in the
regeneration of hepatic cells [2]. Many plant-derived na-
tural products have the potential to be hepatoprotective
and therefore can be used to treat acute and chronic
liver diseases [3-6]. The hepatoprotective activity of tur-
meric (Curcuma longa) or its constituent are reported in
the literature [7-12].
Turmeric is a perennial herb of the ginger family, with
significant antioxidant activity comparable to standard anti-
oxidant such as butylated hydroxyanisole (BHA) [13]. It
can grow up to 1 m high, and has oblong, tufted leaves.
The powder of dried roots and rhizomes of turmeric are
used as one of the spices in Indian curries and other
cuisine. The three major components in turmeric are
curcumin, demethoxycurcumin (DMC) and bisdemethoxy-
curcumin (BDMC) [14].
Numerous studies have shown that curcumin has anti-
oxidant and anti-inflammatory properties [15-17]. Al-
though curcumin has been used throughout history,
especially in India and Asia, the first study on curcumin
and its dose-limiting toxicity was not published until
2001, when it was reported that amounts of up to 8 g, ad-
ministered per day for three months, were not toxic to
humans [18]. Recent evidence has shown that turmeric or
curcumin improve the liver function in rats with hepatic
injury model [7,9-12,19-24].
In view of the hepatoprotective and other beneficial ef-
fects of FTP in animal models, a randomized, double-
blind, placebo-controlled clinical trial was designed and
conducted to evaluate the effects of 12-week FTP treat-
ment on serum aminotransferase levels in subjects with
elevated ALT levels. A significant and clinically relevant
improvement in these parameters would provide a solid
rationale for performing a subsequent trial testing histo-
logical improvement.Methods
Study design and ethics approval
This study was a single-center, randomised, double-blind,
placebo-controlled clinical trial to evaluate the safety and
efficacy of FTP in subjects with elevated ALT levels in
Korea. The principal investigator (PI) initially screened
each potential participant against the inclusion and exclu-
sion criteria. All participants were screened and evaluated
the hepatic ultrasonography, liver function test parameters
(ALT, aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT), total protein, serum albumin, and
total bilirubin (TB)), lipid profiles (total cholesterol (TC),
triglyceride (TG), high density lipoprotein-cholesterol
(HDL-C), and low density lipoprotein-cholesterol (LDL-C)),
and viral hepatitis test (hepatitis B virus (HBV) surface anti-
gen and hepatitis C virus (HCV) antibody). After comple-
ting a screening test, eligible subjects were randomised to
either the FTP or the placebo group. A total of 60
healthy subjects [56 males, 4 females; (mean ± SD) age:
37.6 ± 8.06 y; body mass index (BMI): 27.1 ± 3.4 kg/m2]
were included in this study. All subjects were recruited
from the population of Jeonju-city in Korea. The study
was conducted in accordance with the Declaration of
Helsinki, and written informed consent was obtained from
each participant before allocation. To avoid allocation bias,
concealed allocation using a sealed envelope was employed
in this study. A statistician randomized participants using
computer-generated random table in a 1:1 ratio with block
size 2, and clinical research coordinators (CRC) assigned
them by the random table to receive FTP or placebo treat-
ment. The study was approved by the Functional Foods
Institutional Review Board of Chonbuk National University
Hospital (CUH IRB 2010-02-017), Jeonju, South Korea,
where the study took place.
Inclusion/exclusion criteria
All the subjects enrolled in the study should meet the in-
clusion criteria. The criteria mainly include: (1) age be-
tween 20 and 70 years; (2) ALT levels >40 IU/L measured
at screening in the study laboratory; (3) readiness to
comply with randomisation, treatment and follow-up;
(4) subjects giving written informed consent. Subjects
were excluded if they fulfilled any of the following
criteria: (1) any laboratory (serologies for HBV and
HCV); (2) abnormal transferrin saturation; (3) decompen-
sated cirrhosis; (4) serious disease limiting life expectancy;
(5) pregnancy and lactation.
Study medication
The duration of treatment was 12 weeks, with either
FTP (3.0 g) or placebo (3.0 g) both administered as two
capsules, three times a day orally after meals. Capsules
containing 470 mg lactose and Gardenia yellow color, or
500 mg FTP, were manufactured by Korea INS Pharma-
ceuticals, Inc. (Hwasoon, Jeonnam, South Korea). In
Brief, crushed turmeric was fermented with 2% (wt/wt)
of Aspergillus oryzae at 25°C for 36 h and dried.
We chose single doses to approximate the previously
reported doses from hepatoprotective animal experiment
[23]. Fermented turmeric was standardized to 0.79 mg
curcumin per 1.0 g powder.
Curcumin content of the trial FTP was analysed by the
Korea health supplement Institute using the high perfor-
mance liquid chromatography (HPLC) assay. The amount
Figure 1 Flow chart for the study subjects. AEs, adverse events; ALT, alanine aminotransferase; FTP, fermented turmeric powder; ITT,
intent-to-treat; PP, per protocol.
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curve obtained by the concentration of curcumin standard
against the peak area. Average curcumin contents in
non-fermented turmeric and FTP were approximately
2.0 mg/g and 0.79 mg/g, respectively. The medication was
delivered by the pharmacy of the Clinical Trial Center for
Functional Foods in the Chonbuk National University
Hospital and prescribed regularly to the subjects. The
pharmacy established before the start of the study a list
randomly assigning each subject to 1 of the 2 arms of the
study. The subjects as well as investigators were blinded
to the treatment until completion of the whole study. InTable 1 Baseline characteristics of the study subjects
FTP group (n = 30) Placebo
Sex(M/F) 28/2
Age (years) 39.0 ± 8.5 36
Height (cm) 171.1 ± 6.1 17
Weight (kg) 78.5 ± 10.9 79
BMI (kg/m2) 26.8 ± 3.3 27
SBP (mmHg) 126.6 ± 11.2 129
DBP (mmHg) 79.6 ± 9.3 79
Pulse (BPM) 76.4 ± 12.2 75
Abbreviation: M, male; F, female; SBP, systolic blood pressure; DBP, diastolic blood p
Values are presented as mean ± SD.
1) Analyzed by Independent t-test.
2) Analyzed by Fisher's exact-test.this study, the subjects were not actively asked to change
their lifestyle or to change their diet.
Study end points
The objective of this randomised controlled trial was to
investigate the effects of FTP on serum ALT levels, be-
cause the hypothesis tested was that FTP might improve
liver function. Therefore, serum ALT levels was defined as
the primary end point of the study. Secondary end points
were changes in serum AST, GGT, ALP, and TB levels.
The safety associated with treatment was also assessed by
laboratory tests including glucose, total protein, albumin,group (n = 30) Total (n = 60) P-value1)
28/2 56/4 1.0002)
.2 ± 7.4 37.6 ± 8.1 0.170
0.7 ± 5.8 170.9 ± 5.9 0.770
.6 ± 10.0 79.1 ± 10.4 0.674
.4 ± 3.5 27.1 ± 3.4 0.512
.2 ± 10.3 127.9 ± 10.8 0.341
.8 ± 8.5 79.7 ± 8.8 0.931
.7 ± 7.9 76.1 ± 10.2 0.783
ressure; BPM, beats per minute.
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ment of clinical outcomes were obtained at week 0 (base-
line), 6 and 12. The AEs were recorded at every visit. The
clinical laboratory assessments (hematology, clinical bio-
chemistry and urinalysis) were performed at intervals
throughout the study. The HBV, HCV, and liver ultra-
sounds were also performed at screening visit. Blood pres-
sure, weight and abdominal circumference were measured
every 6 week by a trained research nurse. The question-
naires assessing physical activity, smoking status, alcohol
intake, and general health were administered at baseline
and after each intervention period (at week 6 and 12).
Statistical analysis
For sample size calculation, there was no previous clin-
ical trial to compare the FTP with placebo, therefore,
this study was designed as a pilot study to calculate the
appropriate sample size for future rigorous randomized
clinical trials. We assumed that the primary outcome
was serum ALT levels, whereby 10.2 IU/L was expectedFigure 2 Effects on serum aminotransferase levels. (A) Evolution
of ALT during the study period. Asterisks indicate a difference in
comparison to value at inclusion (*p = 0.019). (B) Evolution of AST
during the study period. Asterisks indicate a difference in comparison
to value at inclusion (*p = 0.020).a clinically relevant difference between the two groups,
with a standard deviation of 14.1, alpha set on 5% and
power on 80%. This resulted in a required number of 24
subjects in each group. With an estimated 20% dropout
rate, we set the total sample size at 60.
All data were entered into a data sheet twice and
reviewed to ensure accuracy. The analyst was blinded to
group allocation. The primary efficacy outcome was
analysed in the modified per-protocol (PP) population, who
completed the study without any major protocol violation.
The assessments of secondary efficacy outcomes, including
serum AST, ALP, GGT, and TB, were primarily based on
the PP population. Differences between treatment groups
were compared using Linear mixed model for repeated
measures data or t-test for continuous variables and chi-
square or Fisher’s exact tests for categorical variables.
All statistical calculations were performed using SAS for
Windows software (version 9.2, SAS institute, Inc., Cary,
NC, USA), and the level of significance was established
at p = 0.05.
Results
Subject disposition and baseline characteristics
Figure 1 shows the flow chart of subject participation in the
trial. A total of 168 subjects were screened, and 60 subjects
were randomised (30 in the FTP group and 30 in the pla-
cebo group). Of 60 randomised subjects, 1 withdrew
consent during the study and 3 discontinued treatment be-
cause of protocol violation (use of prohibited concomitant
medication). Of the 56 subjects, eight subjects were ex-
cluded from the efficacy analysis because of protocol viola-
tion or AEs (abnormal values). Thus, 48 subjects were
included in the PP analysis (n = 26 for FTP, n = 22 for pla-
cebo) (12 subjects were excluded from the PP analysis due
to consent withdrawal, protocol violation or AEs; 4 subjects
in the FTP group and 8 subjects in the placebo group). The
overall compliance in this study was 80%.
Baseline subject characteristics are shown in Table 1.
There were no significant differences between the two
groups. In none of the 2 groups the BMI changed sig-
nificantly during the 12 week, and the mean BMI
remained similar between the 2 groups until completion
of the study. Most subjects were asymptomatic at inclu-
sion and remained so throughout the course of the
study. Throughout the study period, no significant life-
style changes were reported in either treatment group.
Alcohol consumption remained stable throughout the
study period in both groups. Although both kinds of
capsules appeared identical, it is possible that some of
the subjects could discern differences between them.
Efficacy of treatment
Treatment with FTP was associated with a decline in both
ALT and AST levels. These reductions were apparent after
Table 2 Biochemical parameters at baseline (week 0) and end of treatment (week 12) with FTP or placebo in subjects
with elevated ALT levels
FTP group (n = 26) Placebo group (n = 22) P-
value1)Baseline 12 week Baseline 12 week
ALT (IU/L)
Mean ± SD 61.1 ± 25.1 44.9 ± 15.5 55.7 ± 15.1 53.8 ± 26.3 0.019*
Median(Range) 51.5(41–151) 42.5(19–95) 49(40–85) 51(22–127) -
AST (IU/L)
Mean ± SD 36.3 ± 13.8 27.9 ± 7.9 35.6 ± 8.8 34.8 ± 10.9 0.020*
Median(Range) 32.5(20–73) 27(17–46) 34(25–57) 33.5(21–55) -
ALP (IU/L)
Mean ± SD 85.0 ± 19.3 80.0 ± 21.9 71.7 ± 13.5 68.9 ± 13.2 0.471
Median(Range) 81.5(52–144) 79(46–160) 69(48–101) 69(43–92) -
gamma-GT (IU/L)
Mean ± SD 86.3 ± 71.5 66.9 ± 45.6 104.3 ± 69.0 100.8 ± 68.4 0.254
Median(Range) 64(26–360) 52(23–195) 95(16–231) 91(17–253) -
Total bilirubin (mg/dL)
Mean ± SD 0.98 ± 0.46 0.88 ± 0.38 0.89 ± 0.28 0.84 ± 0.26 0.664
Median(Range) 0.87(0.37-2.29) 0.79(0.4-1.98) 0.9(0.37-1.37) 0.81(0.37-1.34) -
Values are presented as mean ± SD.
1. Linear mixed model for repeated measures data.
* P <0.05.
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12-week double-blind treatment period in FTP treatment
groups (Figure 2). The declines in both ALT and AST ob-
served at week 12 were statistically significant compared
with placebo.
The complete data set for all measured parameters is
listed in Table 2. At week 12, the mean ALT reduction was
significantly greater in the FTP group than in the placebo
group (−26.5% vs. -3.4%; p = 0.019). There was alsoFigure 3 Proportion of subjects with ALT normalization at end
of treatment (week 12). NALT, normalized
alanine aminotransferase.observed that the mean AST levels were significantly
reduce in the FTP group than placebo group (−23.1%
vs. -2.2%; p = 0.020). The mean GGT reduction was greater
in the FTP group than in the placebo group, but this reduc-
tion did not reach statistical significance (−22.5% vs. -3.4%;
(p = 0.254). The ALP and total bilirubin levels were not sig-
nificantly affected. Figure 3 shows the proportion of sub-
jects with ALT normalization at week 12. The ALT
normalization rate was significantly higher in the FTP
group than in the placebo group (p = 0.025).
Safety
Results of laboratory testing performed during the study
are shown in Table 3. Laboratory values obtained at base-
line and after completing FTP or placebo treatment were
within acceptable range. There were no significant differ-
ence in any of the blood chemistry parameters among
treatment groups. There were no serious AEs reported
during the study period. Five participants reported AEs
during the study. Two subjects in the Placebo group expe-
rienced mild enteritis and ureterolith, respectively. Three
subjects in the FTP group had chronic gastritis, gout-
induced pain, and common cold, respectively. These five
reports, as judged by the PI, were unlikely related to the
study protocol. These AEs were mild and were pre-
existing complaints before the initiation of treatment with
FTP or placebo. No significant differences in AEs were
found between the two groups.
Table 3 The laboratory findings for safety after the duration of the clinical trial
Turmeric group (n = 26) Placebo group (n = 22) P-
value1)Baseline 12 week Baseline 12 week
WBC (×103/μl) 6.8 ± 1.7 6.7 ± 1.7 6.2 ± 1.4 6.2 ± 1.4 0.79
RBC (×1003/μl) 5.1 ± 0.3 5.1 ± 0.4 5.0 ± 0.3 5.0 ± 0.3 0.36
Hemoglobin (g/dL) 15.9 ± 1.1 15.9 ± 1.2 15.6 ± 1.4 15.7 ± 1.3 0.21
Hematocrit (%) 45.9 ± 2.9 46.0 ± 3.4 44.8 ± 2.9 45.4 ± 3.0 0.37
Platelet (×103/μl) 252.2 ± 49.3 250.3 ± 44.3 255.6 ± 58.5 254.5 ± 62.7 0.92
Total cholesterol (mg/dl) 193.6 ± 25.2 201.7 ± 30.0 194.2 ± 34.7 198.6 ± 31.7 0.62
Triglyceride (mg/dL) 213.3 ± 114.4 220.9 ± 132.8 172.8 ± 78.0 209.4 ± 167.6 0.44
HDL-cholesterol (mg/dL) 44.1 ± 11.8 43.69 ± 11.2 45.8 ± 10.2 48.5 ± 12.1 0.16
LDL-cholesterol (mg/dL) 122.5 ± 29.4 117.3 ± 27.6 125.9 ± 38.9 113.6 ± 27.5 0.33
Glucose (mg/dL) 91.9 ± 9.7 93.0 ± 12.6 90.1 ± 8.7 89.6 ± 8.7 0.52
Total Protein (g/dL) 7.4 ± 0.3 7.48 ± 0.4 7.3 ± 0.4 7.4 ± 0.4 0.73
Albumin (g/dL) 4.6 ± 0.2 4.63 ± 0.2 4.57 ± 0.2 4.6 ± 0.3 0.79
BUN (mg/dL) 14.5 ± 4.7 13.5 ± 3.6 13.3 ± 2.6 12.9 ± 2.8 0.58
Creatinine (mg/dL) 0.85 ± 0.13 0.81 ± 0.14 0.81 ± 0.14 0.83 ± 0.14 0.12
Values are presented as mean ± SD.
1) Linear mixed model for repeated measures data.
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The aim of this study was to evaluate the effects of FTP
on liver function evaluating by aminotransferase levels in
subjects with elevated ALT levels. The results show that
the ingestion of 3.0 g FTP reduced serum aminotransfer-
ase levels in this randomised, double-blind placebo-
controlled trial. In a previous study, reduction in ALT and
AST levels has been observed when 300 mg/kg fermented
turmeric was administered to galactosamine-intoxicated
rats daily for two weeks [23]. In a similar studies on
galactosamine-or carbon tetrachloride-intoxicated ani-
mals, the serum ALT and AST levels were significantly at-
tenuated in animals pretreated with turmeric extract or
fermented turmeric [8,24]. In an in vitro study in which
the effect of curcumin, the principal active compound of
turmeric, on tacrine-induced cytotoxicity in human liver-
derived Hep G2 cells was investigated, curcumin exhibited
hepatoprotective activity [25].
The effectiveness of FTP on hepatic function has not
been studied previously in humans. Liver enzymes ALT
and AST are often used as markers of hepatic function
and their increase in blood indicates liver damage. It is
tempting to speculate that reduction in ALT and AST
levels reflects improvement in hepatic function. Therefore,
data from the current trial, showing a reduction of ALT
and AST levels, suggest that turmeric may improve hep-
atic function. This appears biologically plausible as several
in vivo and in vitro actions of turmeric or curcumin are
consistent with hepatoprotective actions. One of the most
known mechanisms underlying turmeric’s beneficial ef-
fects on hepatic function is its pleiotropic anti-oxidant ac-
tivity [26]. It prevents formation and scavenges reactiveoxygen species (ROS) [27,28] and reactive nitrogen species
[29,30]. Furthermore, curcumin was shown to induce sev-
eral enzymatic anti-oxidants, like glutathione transferase
[31], heme-oxygenase-1 [32] and catalase [31]. Curcumin
inhibits the activation of NF-kB by ROS, protein kinase C
(PKC) and pro-inflammatory cytokines. NF-kB-mediated
expression of inducible nitric oxide synthase (iNOS) is also
inhibited by curcumin [33,34].
In the present study, we measured after 6 weeks and 12 -
weeks of administration of FTP. The results of our study
show that the ingestion of 3.0 g FTP significantly reduced
serum ALT and AST levels without severe AEs, indicating
that turmeric may help improve hepatic disorders. These
findings agree with experimental studies, which have found
that FTP contained with curcumin reduces serum ALT and
AST levels [23,35]. However, a significant reduction in ALP
and total bilirubin levels after supplementation with FTP
was not observed in our study, which can be attributed to
the fact that the ALP and total bilirubin values at baseline
in most of our subjects were in the normal range.
Although the present study has produced promising re-
sults, subject’s health condition (borderline between
healthy person and patient) and small sample size in this
study limits the generalization of our results to other pop-
ulations with hepatic disorders. Another limitation is that
we assessed liver state only by measuring liver enzymes
and did not perform computed tomography scans, MR
scans, or liver biopsies. Finally, the present study was
performed to Korean Food and Drug Administration
(KFDA) approval for health functional food. For this rea-
son, patients with chronic liver disease were excluded
from participating in this study. Therefore, more rigorous
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effects of FTP on hepatic disorders.
Conclusion
In conclusion, FTP significantly reduced serum AST and
ALT levels in subjects with elevated ALT levels. These
effects were maintained for as long as subjects remained
on treatment. FTP was well tolerated and without sig-
nificant AEs. Further studies in larger numbers of sub-
jects, for a longer period of time and with histologic
endpoints, are required to determine whether FTP have
protective beneficial effect on hepatic disorder.
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